Catalyst Edge · Scanner · Tickers · OSTX
CATALYST DOSSIER · UPDATED 2026-11-13

$OSTX

biotech · convergence 3 · conviction WATCH
Convergence Score
3
Conviction
WATCH
Signals Firing
11
Track Record
2/2
Quick tools:🃏 Swipe deck🎯 Today verdict

Price & Live Quote

Loading live quote & chart…

Practice trade tools

Build a reference frame, save a practice trade, or preview a draft. No brokerage order is placed.

Paper trade unavailable: missing risk-bounded frame

Reference only. Not financial advice. No brokerage order is placed.

Why $OSTX?

OSTX 3 WATCH biotech

Quantitative

  • Net Income (CY2026Q2): $-8.6M (-90.3% YoY)

Catalysts

  • Corporate action: warrant_exercise 2026-10-19
  • Dark pool activity: Volume 1.8x 30-day average; price chg -14.0%

Risks

  • Hard-to-borrow / FTD risk: Borrow rate 1.0%, distress score 9

Bear case

  • Squeeze unwind: Short interest can compress before retail catches the move — entry timing critical
  • Earnings binary: Print-day moves can swing ±15% — gap risk both directions

Sympathy basket (cerebro)

  • NVDA via semis r=+0.89 sympathetic (score 46)
  • DIOD via semis r=+0.89 sympathetic (score 31)
  • SKYD via comms r=+0.83 sympathetic (score 22)
  • LBTYA via comms r=+0.83 sympathetic (score 14)
  • BOXL via tech r=+0.77 sympathetic (score 31)
  • CSCO via tech r=+0.77 sympathetic (score 25)

Finance Desk Verdict

Independent agent review — valuation, statement audit, and earnings read on the latest filing.

Valuation: unclearAudit: cautionDesk score: 22/100

Distressed micro-cap rare-oncology biotech at 52-week lows following two high-volume crash events; 8-K catalyst content is unreadable from the bundle — treat as speculative watch only, with the Nov 5 financing-pattern crash and persistent new-low price action as dominant risk signals until filing text can be confirmed.

Bull case: Breakthrough Therapy Designation provides expedited review and stronger FDA dialogue. Osteosarcoma has an enormous unmet need in adolescents; a single positive clinical update or licensing agreement could re-rate the stock sharply from a deeply compressed base. The scanner's priority/quality scores of 70 — combined with gapper_score 15 — suggest the filing may contain a positive milestone. If the Nov 5 crash was an at-the-market offering that funded the balance sheet, the dilution may already be priced in.

Bear case: Two high-volume crash events in 37 trading days signal repeated bad news, not a single one-off shock. The Nov 5 intraday drawdown to $0.58 — consistent with emergency equity issuance — implies management had limited alternatives. If cash runway is now measured in months, further dilution near current prices will compress equity value toward zero. Item 8.01 is a broad disclosure bucket and may be announcing an adverse FDA communication, a clinical hold, a failed partnership negotiation, or additional equity financing. Zero moat score and no analyst coverage remove any institutional price support floor.

Signals Firing

earningsfinra_shortsc13dbiotechsec_fdaaudit_extrasauto_macro_adp_payrollsauto_macro_banrep_colombiaauto_macro_bls_employmentauto_macro_durable_goodsauto_macro_wiki_pageviews
Each tag is a spoke that flagged this ticker today. Weights tuned weekly against published outcomes.

Pick Track Record

DateListNext-day max runNext-day closeHit +2%?
2026-10-05sec_top_gappers+8.8%-6.9%✓ hit
2026-10-05sec_top_moat_emerging+8.8%-6.9%✓ hit
Lifetime: 2/2 wins · hit-rate 100.0% on +2% intraday

Sympathy Basket

Tickers Catalyst Edge tracks as moving with this name. Cross-correlation derived from sector + score-cohort proximity.

Earnings Catalyst

No recent earnings event.

Auto-generated from public filings + tier-1 wires. Catalyst Edge publishes its picks and its losses — see the trust report and methodology. Not financial advice. Confirm independently before trading.

You came here for OSTX. You found it after it moved, the same way everyone else did.

$99 once — every ticker on this site ranked before the open.

Review the methodology and limitations and the dated audit. An intraday price touch is not trading profit.

  1. Click Become a Founding Member below.
  2. Pay $99 once — not monthly, not ever again.
  3. You keep every future release at that price. Tomorrow's ranked list lands at 3:30 AM ET, before the open.
Become a Founding Member — $99 once

One payment, access for as long as we run the service. The free daily picks stay free — this is for people who want the full console. Not buying today? Get tomorrow's ranked list free →

Optional product-learning preferences